CTC Clinical Trial Consultants AB
- Address
- Ebbegatan 3, 582 13 Linköping, Sweden
Bacterial Infections and Mycoses
The site conducts research targeting serious bacterial challenges, focusing on preventing infections caused by pathogenic Escherichia coli strains.
- Vaccine development for invasive extraintestinal pathogenic E. coli
- Evaluation of prophylactic strategies in older adults
- Assessment of microbiological outcomes in bloodstream infections
CTC Clinical Trial Consultants AB leverages its expertise in infectious disease studies to advance preventive solutions.
Cardiovascular Diseases
Trials aim to reduce heart‑related events by testing innovative lipid‑lowering approaches for patients at high risk of atherosclerotic cardiovascular disease.
- Primary prevention of major adverse cardiovascular events
- Comparison of novel RNA‑based therapies with standard care
- Long‑term safety monitoring of cardiovascular outcomes
The research supports the development of therapies that could lower the burden of heart disease across Europe.
Digestive System Diseases
Investigations address disorders of the gut, including efforts to improve treatment options for non‑responsive celiac disease.
- Gluten‑induced mucosal change mitigation
- Adjunctive therapies to a gluten‑free diet
- Biomarker evaluation for intestinal healing
CTC Clinical Trial Consultants AB collaborates with gastroenterology specialists to enhance patient quality of life.
Male Urogenital Diseases
Studies evaluate new oral and injectable agents aimed at restoring function in men with erectile dysfunction.
- Efficacy of novel phosphodiesterase inhibitors
- Safety profiling of emerging sexual health drugs
- Impact on quality‑of‑life measures
The site’s multidisciplinary team ensures rigorous assessment of sexual health interventions.
Nervous System Diseases
Clinical work focuses on acute relief strategies for individuals suffering from severe migraine attacks.
- Rapid‑acting oral therapies for migraine
- Patient‑reported outcome measures
- Consistency of effect across multiple attacks
The research contributes to expanding acute treatment options for headache disorders.
Nutritional and Metabolic Diseases
Research targets weight management and blood‑sugar control, testing agents that may aid patients with obesity and type 2 diabetes.
- Combination therapies for glycemic control
- Weight‑loss efficacy of new compounds
- Safety of long‑term metabolic treatments
CTC Clinical Trial Consultants AB integrates endocrinology expertise to address growing metabolic health challenges.
Respiratory Tract Diseases
Trials investigate treatments designed to lower exacerbation rates in people with chronic obstructive pulmonary disease.
- Evaluation of anti‑inflammatory biologics
- Reduction of hospital admissions
- Long‑term lung function preservation
The site’s pulmonary specialists monitor patient outcomes throughout the study periods.
Virus Diseases
Studies examine novel immunotherapies intended to enhance viral suppression in individuals with chronic hepatitis B infection.
- Combination with nucleoside analogues
- Immunogenicity assessment of new vaccine candidates
- Safety monitoring in long‑term therapy
CTC Clinical Trial Consultants AB collaborates with virology centers to advance therapeutic options for viral liver disease.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 10 by active trials.
No sponsors linked to active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 188 other sites in Sweden
Therapeutic Area Benchmark — Sweden
Select a therapeutic area to compare against other sites in Sweden.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Sweden
Market Share
Country: Sweden
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in CTC Clinical Trial Consultants AB
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE | F. Hoffmann-La Roche AG | Phase III | Not Recruiting | Jul 2023 | Jul 2025 |
IMP list
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Astegolimab | 1 | Unknown | 2023-07-14 | 2023-07-14 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.